Phase I clinical trial design of anticancer agents--a Fibonacci and a modified Fibonacci sequence

H. Kusaba, T. Tamura

研究成果: ジャーナルへの寄稿総説査読

抄録

A Phase I clinical trial of an anticancer agent is the first evaluation in humans, and it is an important step in drug development. From the ethical point of view, the goal is to escalate to the maximum tolerated dose quickly, yet safely, to minimize the likelihood of treating patients at doses that are too low or high. It is expected that the contradictions between safety and efficacy in the Phase I clinical trials will be solved by developing methods. The modified Fibonacci sequence has been generally adopted for dose escalation, although it includes some problems. It is necessary to recognize that the method used for Phase I clinical trials for anticancer agents remains unsatisfactory, and that it is also necessary to develop more ethical and scientific methods.

本文言語英語
ページ(範囲)775-778
ページ数4
ジャーナルGan to kagaku ryoho. Cancer & chemotherapy
27
5
出版ステータス出版済み - 5月 2000
外部発表はい

!!!All Science Journal Classification (ASJC) codes

  • 腫瘍学
  • 癌研究

フィンガープリント

「Phase I clinical trial design of anticancer agents--a Fibonacci and a modified Fibonacci sequence」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル